Search - tctmd.com

Displaying 21 - 40 of 1687

Sort: Relevancy | Date

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

Todd Neale

September 19, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

Caitlin E. Cox

September 05, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Todd Neale

September 03, 2025

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

Presentation ESC 2025

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Presenter: Duk-Woo Park

August 31, 2025

Presentation ESC 2025

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Presenter: Robin Hofmann

August 31, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Opinion CV Team Dispatch

August 2025 Dispatch for the CV Team

L.A. McKeown

August 22, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Advertisement

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

European Experts Provide Advice on Managing CV Effects of COVID-19

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

What’s Going to Be Hot at ESC Congress 2025?

August 2025 Dispatch for the CV Team

DAPT De-escalation Success Varies by Sex: Meta-analysis

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content